Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Jijie Gu"'
Autor:
Haipeng Liu, Hang Su, Fei Wang, Yifang Dang, Yijiu Ren, Shenyi Yin, Huinan Lu, Hang Zhang, Jun Wu, Zhu Xu, Mengge Zheng, Jiani Gao, Yajuan Cao, Junfang Xu, Li Chen, Xiangyang Wu, Mingtong Ma, Long Xu, Fang Wang, Jianxia Chen, Chunxia Su, Chunyan Wu, Huikang Xie, Jijie Gu, Jianzhong Jeff Xi, Baoxue Ge, Yiyan Fei, Chang Chen
Publikováno v:
Cell Reports, Vol 42, Iss 3, Pp 112275- (2023)
Summary: Enhancing chemosensitivity is one of the largest unmet medical needs in cancer therapy. Cyclic GMP-AMP synthase (cGAS) connects genome instability caused by platinum-based chemotherapeutics to type I interferon (IFN) response. Here, by using
Externí odkaz:
https://doaj.org/article/10d05e06853d4217b7c3ab82cc3ec68e
Autor:
Rui Wang, Sean Graham, Ning Sun, Donna McCarthy, Ruoqi Peng, Jamie Erickson, Liz Oconnor, Xiaochun Zhu, Marc Wurbel, Robert Dunstan, Susan Westmoreland, Namjin Chung, Tariq Ghayur, Jijie Gu
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0228221 (2020)
Inflammatory bowel diseases (IBD) are complex, multifactorial disorders characterized by chronic relapsing intestinal inflammation. IBD is diagnosed around 1 in 1000 individuals in Western countries with globally increasing incident rates. Associatio
Externí odkaz:
https://doaj.org/article/a04ed1706d0a49edb315c6d7dab23a95
Autor:
Philip D. Bardwell, Matthew M. Staron, Junjian Liu, Qingfeng Tao, Susanne Scesney, Gail Bukofzer, Luis E. Rodriguez, Chee-Ho Choi, Jennifer Wang, Qing Chang, Feng Dong, Cherrie Donawho, Jieyi Wang, Christine M. Grinnell, Edit Tarcsa, Charles Hutchins, Tariq Ghayur, Jijie Gu
Publikováno v:
Protein & Cell, Vol 9, Iss 1, Pp 121-129 (2017)
Abstract Novel biologics that redirect cytotoxic T lymphocytes (CTLs) to kill tumor cells bearing a tumor associated antigen hold great promise in the clinic. However, the ability to safely and potently target CD3 on CTL toward tumor associated antig
Externí odkaz:
https://doaj.org/article/7d9af6e5d86246a79205f69880a28694
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0124135 (2015)
Epidermal growth factor receptor (EGFR) and receptor tyrosine-protein kinase 3 (ErbB3) are two well-established targets in cancer therapy. There is significant crosstalk among these two receptors and others. To block signaling from both EGFR and ErbB
Externí odkaz:
https://doaj.org/article/6e62913031864fef962f7da427a32698
Autor:
Jinming Gu, Jinsong Yang, Qing Chang, Xiaoqing Lu, Jieyi Wang, Mingjiu Chen, Tariq Ghayur, Jijie Gu
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97292 (2014)
Inhibiting ErbB2 signaling with monoclonal antibodies (mAbs) or small molecules is an established therapeutic strategy in oncology. We have developed anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig) proteins that capture the function of a comb
Externí odkaz:
https://doaj.org/article/04b66a2bcde548e28545c752fc2bb067
Publikováno v:
Antibody Therapeutics. 6:13-29
Developability refers to the likelihood that an antibody candidate will become a manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug candidate will be well considered by sponsors and regulatory agencies, developabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7950eadd9c303a8f3ec853b39a81d47
https://doi.org/10.1093/abt/tbac029
https://doi.org/10.1093/abt/tbac029
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Table S1: ABT-165 binding affinity; Table S2: ABT-165 in vitro potency; Table S3: Effect of VEGF on anti-DLL4 cellular potency of ABT-165; Table S4: Summary of in vivo efficacy; Table S5: Key safety findings of ABT-487 and ABT-165; Figure S1: Serum c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948fdfba3f05b8a422e19034176fe36d
https://doi.org/10.1158/1535-7163.22505686
https://doi.org/10.1158/1535-7163.22505686
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
This file describes the binding assay details of surface plasmon resonance technology, ligand and receptor binding competition assays, western blot detection of DLL4 protein down-regulation, and the methods to measure total circulating soluble DLL4 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267ca9367d459176dea46bdd55158c64
https://doi.org/10.1158/1535-7163.22505689.v1
https://doi.org/10.1158/1535-7163.22505689.v1
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2454e519448df5024c51607be68974ce
https://doi.org/10.1158/1535-7163.c.6538150.v1
https://doi.org/10.1158/1535-7163.c.6538150.v1
Publikováno v:
Antib Ther
A bispecific antibody (bsAb) is able to bind two different targets or two distinct epitopes on the same target. Broadly speaking, bsAbs can include any single molecule entity containing dual specificities with at least one being antigen-binding antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f5164e5a5d54284316fa589dd2fc50
https://europepmc.org/articles/PMC7990219/
https://europepmc.org/articles/PMC7990219/